PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lewiecki EM - Denosumab is a promising therapeutic agent for the management of postmenopausal osteoporosis and rheumatoid arthritis.

Related Articles

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The Journal of Urology, 11/16/09    Relevance Score: 87%

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09    Relevance Score: 83%

Bone health and prostate cancer
Prostate Cancer & Prostatic Diseases, 11/13/09    Relevance Score: 77%

Today in Clinical Pharmacology...keeping you current

Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/07/09

Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention
Evidence-Based Medicine, 12/07/09

Benefits of budesonide or nedocromil for mild to moderate asthma in children were not sustained after discontinuation
Evidence-Based Medicine, 12/07/09

Today in Women`s Health...keeping you current

HPV-16/18 vaccine is highly effective in preventing precancerous cervical lesions
The Clinical Advisor, 12/07/09

Correlates of use of antifracture therapy in older women with low bone mineral density
Journal of General Internal Medicine, 12/07/09

Adjuvant Phytotherapy in the Treatment of Cervical Cancer: A Systematic Review and Meta-Analysis
Journal of Alternative and Complementary Medicine, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address